Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes Inadequately Controlled by Insulin Therapy
NCT06762314Phase 2Completed
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of semaglutide and empagliflozin in type 1 diabetes mellitus (T1D) (3 arms). Primary endpoint: Glycated Haemoglobin at 3 months. Started Jan 2025; status: completed.
02
Drugs
semaglutideempagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06762314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762314.